Abstract: Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.
Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
January 18, 2011
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
David Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
January 11, 2011
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Christoph Reinhard, Anne Bennett Jefferson, Vivien W. Chan, Joerg Kaufmann, Hong Xin, Giulia C. Kennedy, Greg Harrowe, Hamiduddin Khoja, Venkatakrishna Shyamala
Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, and alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens, as well as to methods of making and using the immunogenic compositions.
Type:
Application
Filed:
June 1, 2010
Publication date:
January 6, 2011
Applicant:
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Inventors:
Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
Type:
Application
Filed:
July 28, 2010
Publication date:
December 30, 2010
Applicants:
NOVARTIS VACCINES AND DIAGNOSTICS, INC., WASHINGTON UNIVERSITY
Inventors:
Thomas W. Dubensky, JR., John M. Polo, Barbara A. Belli, Sergey A. Dryga, Sondra Schlessinger, Ilya Frolov
Abstract: A variety of low molecular weight, guanidino-containing dihydroisoquinolinoines capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure ID where the values of the variable are defined herein.
Type:
Grant
Filed:
October 11, 2005
Date of Patent:
December 28, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 ?g/kg to 36 ?g/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof.
Type:
Grant
Filed:
February 24, 2009
Date of Patent:
December 28, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Martha J. Whitehouse, W. Michael Kavanaugh
Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein.
Type:
Grant
Filed:
May 23, 2003
Date of Patent:
December 28, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
Abstract: Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
Type:
Grant
Filed:
January 24, 2005
Date of Patent:
December 21, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Weibo Wang, Zhi-Jie Ni, Paul Barsanti, Sabina Pecchi, Yi Xia, Nathan Brammeier, Megan C. Phillips, Eliza Jazan, Kelly Wayman, David Dibble, Jie-Kai Cheng
Abstract: A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided.
Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.
Type:
Application
Filed:
November 17, 2009
Publication date:
December 16, 2010
Applicants:
Novartis Vaccines and Diagnostics, Inc., University of Stellenbosch
Inventors:
Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensburg
Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).
Type:
Grant
Filed:
January 8, 2004
Date of Patent:
December 14, 2010
Assignees:
Novartis Vaccines and Diagnostics, Inc., Pharmacia & Upjohn Company
Inventors:
David H. Reifsnyder, Duane Inlow, Glenn Dorin, Patricio T. Riquelme, Cynthia A. Cowgill, Douglas G. Bolesch, Mark E. Gustafson
Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
Abstract: Microparticles with adsorbed complexes of macromolecule and detergent, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surfaces of the microparticles have adsorbed thereon a complex of biologically active macromolecules, such as nucleic acids, polypeptides, antigens, and adjuvants, and a detergent. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferably those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 30,000 Daltons to 70,000 Daltons. Preferred macromolecules are bacterial and viral antigens (such as HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens) as well as polynucleotides that encode for such antigens.
Type:
Grant
Filed:
February 10, 2004
Date of Patent:
December 7, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Jia-Hwa Fang, Manmohan Singh, Derek O'Hagan, Maninder Hora
Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
Abstract: Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.
Type:
Grant
Filed:
November 12, 2003
Date of Patent:
November 23, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Alison Hannah, Eric Harwood, Peter Haroldsen, Carla Heise, Timothy Machajewski, Emil Samara, Xiao Shang, Jayesh Vora, Shuguang Zhu
Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
Abstract: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.
Type:
Grant
Filed:
November 5, 2004
Date of Patent:
November 2, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Shaopei Cai, Joyce Chou, Eric Harwood, Carla C. Heise, Timothy D. Machajewski, David Ryckman, Xiao Shang, Marion Wiesmann, Shuguang Zhu
Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
Type:
Grant
Filed:
October 24, 2007
Date of Patent:
November 2, 2010
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner